Subscribe To
TEVA / 2 "Safe" Stocks That Are Anything But
TEVA News
By Reuters
October 10, 2023
Drugmaker Teva does not see big impact on business from Israel-Hamas war
Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday. more_horizontal
By See It Market
September 12, 2023
TEVA: A Pharmaceutical Stock to Watch Right Now
Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have more_horizontal
By Seeking Alpha
September 11, 2023
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 8:40 AM ET Co more_horizontal
By Seeking Alpha
August 26, 2023
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. more_horizontal
By Zacks Investment Research
August 23, 2023
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 an more_horizontal
By Zacks Investment Research
August 22, 2023
TEVA to Pay $250 Million to Settle Price-Fixing Charges
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 an more_horizontal
By Proactive Investors
August 22, 2023
Teva Pharma lands US$225 million fine for price-fixing
Generic drug maker Teva Pharmaceuticals is to pay US $225 million in fines after admitting price-fixing on a range of drugs in the US. Teva and anothe more_horizontal
By CNN Business
August 21, 2023
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges
Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholestoral to settle price-fixing charges f more_horizontal